Leukaemia

The targeted drug gilteritinib is now recommended for some adults with acute myeloid leukaemia (AML) on the NHS in England.  

The Scottish Medicines Consortium (SMC) has accepted 3 new cancer treatments for NHS use in Scotland

Leukaemia and head and neck cancer drugs have not been recommended for NHS use in England.

A targeted combination treatment for patients with a specific type of blood cancer will soon be available on the NHS in Scotland.

A breast cancer drug and two blood cancer treatments have been recommended for use on the NHS in Scotland.

Patients living with a specific type of leukaemia will have access to a new immunotherapy treatment on the NHS in England.

Three cancer drugs have been approved for patients on the NHS in Scotland, including a drug for some patients with advanced liver cancer.

Patients with a specific type of leukaemia will not have access to a new treatment after it failed to win provisional recommendation for NHS use in England.

Two cancer immunotherapies have been reviewed for NHS use in Scotland as a treatment for some patients with aggressive blood cancer.

An 11-year-old boy became the first NHS patient to receive a personalised blood cancer immunotherapy on the NHS.